公开(公告)号：US10456354B1

公开(公告)日：2019-10-29

申请号：US16176866

申请日：2018-10-31

申请人： Slayback Pharma LLC

发明人： Rahul Dhulaji Bhise ,  Ajay Kumar Singh ,  Mahadeo Vasant Mahadik ,  Ashish Anilrao Dubewar ,  Molugu Prashanth Reddy

IPC分类号： A61K31/27 ,  A61K31/401 ,  A61K9/00 ,  A61K47/18 ,  A61K31/40 ,  A61K9/08

摘要： The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

公开(公告)号：US11938217B2

公开(公告)日：2024-03-26

申请号：US18098505

申请日：2023-01-18

申请人： SLAYBACK PHARMA LLC

发明人： Rahul Dhulaji Bhise ,  Ajay Kumar Singh ,  Mahadeo Vasant Mahadik ,  Ashish Anilrao Dubewar ,  Molugu Prashanth Reddy

IPC分类号： A61K31/27 ,  A61K9/00 ,  A61K9/08 ,  A61K31/40 ,  A61K47/18

CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K31/27 ,  A61K31/40 ,  A61K47/183

摘要： Stable, ready-to-use injectable pharmaceutical compositions are provided, comprising the combination of neostigmine, glycopyrrolate, and a pharmaceutically acceptable liquid vehicle, optionally with additional pharmaceutically acceptable excipients. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

公开(公告)号：US11110054B2

公开(公告)日：2021-09-07

申请号：US16170948

申请日：2018-10-25

申请人： Slayback Pharma LLC

发明人： Rahul Dhulaji Bhise ,  Ajay Kumar Singh ,  Mahadeo Vasant Mahadik ,  Ashish Anilrao Dubewar ,  Molugu Prashanth Reddy

IPC分类号： A61K31/27 ,  A61K31/40 ,  A61K9/00 ,  A61K9/08 ,  A61K47/18

摘要： The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.